|Animal Health Trust, Newmarket, England.
AHT is an independent trust working within animal health since more than 50 years and has more than 200 employees, including research staff and clinicians. AHT is one of the few institutions in Europe where experimental infections classified as high risk to the environment can be performed. At the Allen Centre facility, Intervacc has tested its prototype vaccines in horses.
|Moredun Scientific, Edinburgh, Skottland.
Clinical trials, pigs
|The Swedish University of Agricultural Sciences (SLU), Uppsala.|
|Karolinska Institute, KI, Stockholm.
|3P Biopharmaceuticals, Pamplona, Spain
3P Biopharmaceuticals is our partner for contract manufacturing of Strangvac®, Intervacc´s recombinant vaccine against strangles. The collaboration between the Companies covers transfer of the manufacturing technology, production of validation batches and long term future commercial manufacturing.
|PX´Therapeutics, Grenoble, Frankrike
PX'Therapeutics, a subsidiary of Aguettant pharmaceuticals, has been engaged by Intervacc to streamline the production process of Strangvac® for commercial large-scale GMP manufacturing. The business group has the experience, equipment and staff to optimize processes to produce recombinant E. coli proteins.
Analyses of Strangvac® for stability studies
|Novavax AB, Uppsala
Novavax have developed a patented technology that enhances the effect of vaccines (adjuvants). The technique is based on different immune-stimulating components, saponins, which are extracted from the tree Quillaja saponaria. Following purification the immune-stimulating components produce different complexes named iscomes. Iscomes are included in several authorised vaccines amongst one of which is a vaccine against horse influensa. Intervacc has an agreement with Novavax to use the iscome technology in its strangles vaccine.
|Sofus Regulatory Affairs, Stockholm
|AWA Patent, Stockholm
|Ernst & Young, Stockholm
Financial and strategic advisory